Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Board of Directors
Candel Therapeutics expanded its Board from ten to eleven directors and appointed Martine Zimmermann, Pharm.D., as an independent director effective September 8, 2026. The company said her regulatory and quality expertise supports its planned Biologics License Application submission for aglatimagene besadenovec in the fourth quarter of 2026.
Key points
- Board size increased from ten to eleven directors; Zimmermann appointed September 6, 2026, effective September 8, 2026
- Zimmermann receives an option to purchase 64,000 shares of common stock, vesting in equal monthly installments over three years
- Annual Board retainer of $40,000, paid quarterly in arrears and pro-rated for days served
- Zimmermann is Executive Vice President at Inventiva S.A. and a director of Nasdaq-listed Ligand Pharmaceuticals since October 2023
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.